Letter to the editor: Six‐month antibody kinetics and durability in liver transplant recipients after two doses of SARS‐CoV‐2 mRNA vaccination

Amy Chang, Alexandra T. Strauss, Jennifer L. Alejo, Teresa P.‐Y. Chiang, Nicole F. Hernandez, Laura B. Zeiser, Brian J. Boyarsky, Robin K. Avery, Aaron A. R. Tobian, Macey L. Levan, Daniel S. Warren, Jacqueline M. Garonzik‐Wang, Allan B. Massie, William A. Werbel, Dorry L. Segev – 4 July 2022

Ranking of transarterial and targeted therapies for advanced hepatocellular carcinoma in the era of immuno‐oncology: A network meta‐analysis of randomized sorafenib‐controlled trials

Jihyun An, Seungbong Han, Ha Il Kim, Ju Hyun Shim – 3 July 2022 – To date, no studies have compared the new first‐line atezolizumab+bevacizumab with transarterial therapies combined with the prior standard‐of‐care, sorafenib, in patients with advanced hepatocellular carcinoma (HCC). We compared and ranked all relevant transarterial and targeted treatments competing with atezolizumab+bevacizumab for such disease, based on direct and indirect evidence.

Reply

Coralie Amadou, Oumarou Nabi, Lawrence Serfaty, Karine Lacombe, Jérôme Boursier, Philippe Mathurin, Céline Ribet, Victor Ledinghen, Marie Zins, Marie‐Aline Charles – 2 July 2022

Subscribe to